DSS, Inc. Announces SEC Declaration of Effectiveness of Form F-4 Registration Statement, Marking Major Milestone Toward Closing of Proposed Business Combination

Impact Biomedical scheduled a special stockholder meeting for November 13, 2026, at 10:00 a.m. Eastern Standard Time to vote on its proposed business combination. If the transaction closes, the combined company is expected to operate as Zoar Limited and trade on NYSE American under ticker ZOAR, subject to listing approval.

Analysis

The scheduled vote is a near-term binary catalyst, but the announcement alone does not establish the transaction’s economic value or likelihood of closing. Treat the proposed name and ticker change as conditional—not evidence that listing approval or the business combination is assured. The key market mechanism is event risk: a favorable vote may remove one hurdle without resolving other closing conditions, while a failed or delayed vote could leave IBO exposed to a sharper repricing and weaker liquidity. Over the next 1–3 months, the decisive inputs are the proxy’s deal economics, shareholder voting and any applicable cash-election or redemption terms, remaining conditions, and NYSE American’s listing decision. Over 6–18 months, the question is whether the post-combination business can support the valuation implied by the transaction; none of that can be assessed from this notice. Contrarian read: the meeting date is more useful as a diligence deadline than as a bullish signal. Without transaction terms or evidence of operating performance, there is no sound basis to underwrite upside from the proposed ticker change.

Key Decisions for Investors

• No directional IBO trade on this notice alone. Before taking event exposure, review the proxy for consideration, pro forma ownership and dilution, financing, closing conditions, and any shareholder cash-election or redemption provisions.
• Monitor the November 13 vote and subsequent listing/closing announcements as separate gates; a favorable vote is not equivalent to a completed transaction or NYSE American listing.
• For any existing IBO position, size for the possibility of a failed or adjourned vote and potential liquidity deterioration. Reassess if the vote outcome, listing decision, or disclosed deal terms materially differ from expectations.
• Falsifiers for a constructive view: a failed or delayed vote, denial of listing approval, adverse financing or dilution terms, or later disclosures that undermine the post-combination valuation.